BMS and AbbVie’s myeloma drug Empliciti gains approval

Multiple myeloma, one of the fastest-moving therapy areas, has just added another new treatment following FDA approval of Bristol-Myers Squibb's (BMS) and AbbVie's Empliciti (elotuzumab).